Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model

Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model

American Journal of Ophthalmology ◽

10.1016/s0002-9394(00)00689-9 ◽

2000 ◽

Vol 130 (6) ◽

pp. 717-723 ◽

Cited By ~ 18

Author(s):

Peter A Netland ◽

Charles Leahy ◽

Kathleen L Krenzer

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Ophthalmic Suspension

Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: A single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis

Clinical Therapeutics ◽

10.1016/s0149-2918(08)80051-3 ◽

2008 ◽

Vol 30 (7) ◽

pp. 1272-1282 ◽

Cited By ~ 10

Author(s):

Gail L. Torkildsen ◽

Mark B. Abelson ◽

Paul J. Gomes

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Single Center ◽

Ketotifen Fumarate ◽

Evaluation of Comfort Using Olopatadine Hydrochloride 0.1% Ophthalmic Solution in the Treatment of Allergic Conjunctivitis in Contact Lens Wearers Compared to Placebo Using the Conjunctival Allergen-Challenge Model

Eye & Contact Lens Science & Clinical Practice ◽

10.1097/01.icl.0000063576.32087.f7 ◽

2003 ◽

Vol 29 (2) ◽

pp. 113-116 ◽

Cited By ~ 14

Author(s):

Miguel Brodsky ◽

William E. Berger ◽

Salim Butrus ◽

Arthur B. Epstein ◽

Murat Irkec

Keyword(s):

Contact Lens ◽

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Olopatadine Hydrochloride

Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model

Cornea ◽

10.1097/ico.0000000000000562 ◽

2015 ◽

Vol 34 (10) ◽

pp. 1245-1251 ◽

Cited By ~ 7

Author(s):

Eugene McLaurin ◽

Abhijit Narvekar ◽

Paul Gomes ◽

Adeniyi Adewale ◽

Gail Torkildsen

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Efficacy And Safety ◽

Phase 3 ◽

Once Daily ◽

Olopatadine Hydrochloride

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

Allergy and Asthma Proceedings ◽

10.2500/aap.2012.33.3570 ◽

2012 ◽

Vol 33 (3) ◽

pp. 265-274 ◽

Cited By ~ 6

Author(s):

Edward J. Meier ◽

Gail L. Torkildsen ◽

James A. Gow ◽

Timothy R. McNamara ◽

Paul J. Gomes ◽

...

Keyword(s):

Allergic Conjunctivitis ◽

Ophthalmic Solution ◽

Phase Iii ◽

Ocular Itching ◽

Phase Iii Trials

Bepotastine Besilate Ophthalmic Solution 1.5% Produces Strong Clinical Benefit for Ocular Itching Immediately Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2010.12.1021 ◽

2011 ◽

Vol 127 (2) ◽

pp. AB256-AB256

Author(s):

J.C. Clark ◽

J.I. Williams ◽

P.J. Gomes ◽

M.B. Abelson ◽

J.A. Gow ◽

...

Keyword(s):

Clinical Benefit ◽

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Ocular Itching ◽

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children

Clinical Therapeutics ◽

10.1016/j.clinthera.2009.09.001 ◽

2009 ◽

Vol 31 (9) ◽

pp. 1908-1921 ◽

Cited By ~ 23

Author(s):

Mark B. Abelson ◽

Gail L. Torkildsen ◽

Jon I. Williams ◽

James A. Gow ◽

Paul J. Gomes ◽

...

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Phase Iii ◽

Single Center ◽

Duration Of Action ◽

Adults And Children ◽

Time To Onset ◽

Ophthalmic Solutions

An Evaluation of Onset and Duration of Action of Patanol® (Olopatadine Hydrochloride Ophthalmic Solution 0.1%) Compared to Claritin® (Loratadine 10 mg) Tablets in Acute Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model

Acta Ophthalmologica Scandinavica ◽

10.1034/j.1600-0420.2000.078s230060.x ◽

2000 ◽

Vol 78 ◽

pp. 60-63 ◽

Cited By ~ 40

Author(s):

Mark B. Abelson ◽

Donna L. Welch

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Duration Of Action ◽

Olopatadine Hydrochloride

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2010.12.1022 ◽

2011 ◽

Vol 127 (2) ◽

pp. AB257-AB257

Author(s):

J.I. Williams ◽

E.B. McLaurin ◽

F.K. Kurata ◽

M.B. Abelson ◽

J.A. Gow ◽

...

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom (NOCS) Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2010.12.1016 ◽

2011 ◽

Vol 127 (2) ◽

pp. AB255-AB255

Author(s):

J.A. Gow ◽

T.T. Macejko ◽

M.T. Bergmann ◽

E. Meier ◽

M.B. Abelson ◽

...

Keyword(s):

Allergic Conjunctivitis ◽

Allergen Challenge ◽

Ophthalmic Solution ◽